Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.
Journal
Gastrointestinal endoscopy
ISSN: 1097-6779
Titre abrégé: Gastrointest Endosc
Pays: United States
ID NLM: 0010505
Informations de publication
Date de publication:
02 2019
02 2019
Historique:
received:
09
06
2018
accepted:
24
09
2018
pubmed:
21
10
2018
medline:
22
5
2019
entrez:
21
10
2018
Statut:
ppublish
Résumé
Data on time trends of dysplasia and esophageal adenocarcinoma (EAC) in Barrett's esophagus (BE) during the index endoscopy (ie, prevalent cases) are limited. Our aim was to determine the prevalence patterns of BE-associated dysplasia on index endoscopy over the past 25 years. The Barrett's Esophagus Study is a multicenter outcome project of a large cohort of patients with BE. Proportions of patients with index endoscopy findings of no dysplasia (NDBE), low-grade dysplasia (LGD), high-grade dysplasia (HGD), and EAC were extracted per year of index endoscopy, and 5-yearly patient cohorts were tabulated over years 1990 to 2010+ (2010-current). Prevalent dysplasia and endoscopic findings were trended over the past 25 years using percentage dysplasia (LGD, HGD, EAC, and HGD/EAC) to assess changes in detection of BE-associated dysplasia over the last 25 years. Statistical analysis was done using SAS version 9.4 software (SAS, Cary, NC). A total of 3643 patients were included in the analysis with index endoscopy showing NDBE in 2513 (70.1%), LGD in 412 (11.5%), HGD in 193 (5.4%), and EAC in 181 (5.1%). Over time, there was an increase in the mean age of patients with BE (51.7 ± 29 years vs 62.6 ± 11.3 years) and the proportion of males (84% vs 92.6%) diagnosed with BE but a decrease in the mean BE length (4.4±4.3 cm vs 2.9±3.0 cm) as time progressed (1990-1994 to 2010-2016 time periods). The presence of LGD on index endoscopy remained stable over 1990 to 2016. However, a significant increase (148% in HGD and 112% in EAC) in the diagnosis of HGD, EAC, and HGD/EAC was noted on index endoscopy over the last 25 years (P < .001). There was also a significant increase in the detection of visible lesions on index endoscopy (1990-1994, 5.1%; to 2005-2009, 6.3%; and 2010+, 16.3%) during the same period. Our results suggest that the prevalence of HGD and EAC has significantly increased over the past 25 years despite a decrease in BE length during the same period. This increase parallels an increase in the detection of visible lesions, suggesting that a careful examination at the index examination is crucial.
Identifiants
pubmed: 30342028
pii: S0016-5107(18)33174-2
doi: 10.1016/j.gie.2018.09.041
pmc: PMC7053563
mid: NIHMS1563198
pii:
doi:
Types de publication
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
257-263.e3Subventions
Organisme : NCI NIH HHS
ID : U54 CA163060
Pays : United States
Informations de copyright
Copyright © 2019 American Society for Gastrointestinal Endoscopy. Published by Elsevier Inc. All rights reserved.
Références
Am J Gastroenterol. 2008 Nov;103(11):2694-9
pubmed: 18853967
Int J Epidemiol. 2000 Aug;29(4):645-54
pubmed: 10922340
J Natl Cancer Inst. 2005 Jan 19;97(2):142-6
pubmed: 15657344
Eur J Epidemiol. 2011 Sep;26(9):739-45
pubmed: 21671079
N Engl J Med. 2011 Oct 13;365(15):1375-83
pubmed: 21995385
Am J Gastroenterol. 2006 Jun;101(6):1178-82
pubmed: 16771933
Gastroenterology. 2016 Mar;150(3):599-607.e7; quiz e14-5
pubmed: 26619962
Gut. 2001 Mar;48(3):304-9
pubmed: 11171817
Aliment Pharmacol Ther. 2004 Jun 15;19(12):1255-60
pubmed: 15191506
Br J Cancer. 2009 Sep 1;101(5):855-9
pubmed: 19672254
Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):997-1006
pubmed: 24692500
Dis Esophagus. 2015 Jul;28(5):418-21
pubmed: 24708395
J Natl Cancer Inst. 2011 Jul 6;103(13):1049-57
pubmed: 21680910
Gastroenterology. 2011 Mar;140(3):1084-91
pubmed: 21376940
Lancet. 1997 Sep 27;350(9082):933
pubmed: 9314878
Gastroenterology. 2017 Apr;152(5):987-992
pubmed: 27988383
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
pubmed: 21296855
Gastrointest Endosc Clin N Am. 2017 Jul;27(3):353-364
pubmed: 28577761
Am J Gastroenterol. 2016 Jan;111(1):30-50; quiz 51
pubmed: 26526079
Gastroenterology. 2011 Mar;140(3):e18-52; quiz e13
pubmed: 21376939
Clin Gastroenterol Hepatol. 2004 Apr;2(4):296-300
pubmed: 15067623
Int J Cancer. 2002 Jun 20;99(6):860-8
pubmed: 12115489
Cancer. 1998 Nov 15;83(10):2049-53
pubmed: 9827707
J Gastroenterol Hepatol. 1998 Apr;13(4):356-62
pubmed: 9641297
Gut. 2005 Aug;54(8):1062-6
pubmed: 15857935
Gastrointest Endosc. 2012 Dec;76(6):1087-94
pubmed: 23164510
Int J Cancer. 2008 Mar 1;122(5):1118-29
pubmed: 17990321
Gut. 1997 Sep;41(3):303-7
pubmed: 9378382
Ann Oncol. 2012 Dec;23(12):3155-62
pubmed: 22847812
Gastrointest Endosc. 2012 Sep;76(3):531-8
pubmed: 22732877
Semin Oncol. 1999 Oct;26(5 Suppl 15):2-8
pubmed: 10566604